SCHEMBL5842151

SCHEMBL5842151

Nc1ccc(N(CC2CC2)c2ccccc2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.50
CYP3A4 P08684 3/20 0.50
TDP1 Q9NUW8 3/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
KDM4E B2RXH2 1/20 0.50
CYP1A2 P05177 1/20 0.50
CYP2D6 P10635 1/20 0.50
MAPT P10636 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
FGFR1 P11362 3/20 0.41
FGFR2 P21802 3/20 0.41
FGFR3 P22607 3/20 0.41
KDR P35968 3/20 0.41
FGFR4 P22455 2/20 0.41
HSD17B10 Q99714 2/20 0.38
USP2 O75604 1/20 0.38
HPGD P15428 1/20 0.38
LTC4S Q16873 2/20 0.38
REN P00797 5/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25262182 0.81 FGFR1 (0.41) ALDH1A1TDP1FGFR1FGFR2FGFR3
SCHEMBL18658375 0.80 OPRM1 (0.52) ALDH1A1KDM4EFGFR1FGFR2FGFR3
SCHEMBL29116510 0.79 OPRM1 (0.46) ALDH1A1KDM4EFGFR1FGFR2FGFR3
SCHEMBL5842999 0.78 FGFR1 (0.38) ALDH1A1FGFR1FGFR2FGFR3KDR
SCHEMBL21016554 0.76 LTC4S (0.51) ALDH1A1FGFR1FGFR2FGFR3KDR
SCHEMBL18979892 0.76 CYP3A4 (0.62) ALDH1A1CYP3A4TDP1L3MBTL1KDM4E
SCHEMBL25255886 0.75 REN (0.45) ALDH1A1FGFR1FGFR2FGFR3KDR
SCHEMBL5843310 0.72 CYP3A4 (0.64) ALDH1A1CYP3A4TDP1L3MBTL1KDM4E
SCHEMBL6477206 0.72 OPRM1 (0.42) ALDH1A1CYP3A4TDP1L3MBTL1KDM4E
SCHEMBL18421862 0.71 SLC6A2 (0.45) CYP3A4CYP1A2CYP2D6CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050192292-A1 Pyrrolidone carboxamides ACTELION PHARMACEUTICALS AG (CH) 2005-09-01 US claimed
CN-100534990-C Pyrrolidone carboxamides ACTELION PHARMACEUTICALS LTD (CH) 2009-09-02 CN disclosed
US-7067549-B2 Pyrrolidone carboxamides ACTELION PHARMACEUTICALS AG (CH) 2006-06-27 US disclosed
US-20050192292-A1 Pyrrolidone carboxamides ACTELION PHARMACEUTICALS AG (CH) 2005-09-01 US disclosed
CN-1610678-A Pyrrolidone carboxamides ACTELION PHARMACEUTICALS LTD (CH) 2005-04-27 CN disclosed
EP-1463724-A1 PYRROLIDONE CARBOXAMIDES Actelion Pharmaceuticals Ltd. (CH) 2004-10-06 EP disclosed
WO-2003059905-A1 PYRROLIDONE CARBOXAMIDES ACTELION PHARMACEUTICALS LTD (CH) 2003-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050192292-A1 Pyrrolidone carboxamides NPY1R, NPY5R, NPY2R ALDH1A1 3034/4885CYP3A4 1975/4885TDP1 3359/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.